AIM4ALL provides Health Systems with a structured pathway from fragmented, siloed data environments and one-off access and reimbursement negotiations to a modern model of innovation partnership, longitudinal data insights, and scalable, repeatable service delivery.

Designed to strengthen Health Systems with minimal additional operational burden, the AIM4ALL approach enhances their attractiveness as destinations of choice for clinical trials while supporting earlier, more sustainable access to high-cost innovative medicines.

It achieves this by:

-          Generating payer-relevant evidence earlier in the product lifecycle,

-          Reducing uncertainty in Health Technology Assessment (HTA) and reimbursement decision-making,

-          Supporting the implementation of innovative value-based contracting models,

-          Addressing affordability challenges through improved evidence and outcomes visibility, and

-          Providing Pharmaceutical Manufacturers with greater visibility of acceptable MFN net launch pricing.

Participation in the AIM4ALL Global Alliance of Health Systems further amplifies the value of national data assets. Through a federated approach, Health Systems can contribute to and benefit from cross-jurisdictional insights and benchmarking while retaining full control of their data and preserving national data sovereignty.